Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells

British Journal of Cancer

Volumn 102, Issue 4, 2010, Pages 754-764

  Mahalingam, D ^a,b   Natoni, A ^a   Keane, M ^c   Samali, A ^a   Szegezdi, E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b San Antonio Cancer Institute   (United States)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Cellular FLICE inhibitory protein (c FLIP); Colon carcinoma; Death receptor 5 (DR5); Early growth response gene 1 (Egr 1); Tumour necrosis factor related apoptosis inducing ligand (TRAIL); Type I extrinsic apoptotic pathway

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; EARLY GROWTH RESPONSE FACTOR 1; FLICE INHIBITORY PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; KNOCKOUT GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SENSITIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; COLONIC NEOPLASMS; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; MUTANT PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 76949102583     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605545     Document Type: Article

References (51)

1. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, Gordon JI, Humphrey PA, Milbrandt J (2001) Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7: 101-107
2. Ahmed MM (2004) Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr Cancer Drug Targets 4: 43-52
3. Al-Sarraj A, Day RM, Thiel G (2005) Specificity of transcriptional regulation by the zinc finger transcription factors Sp1, Sp3, and Egr-1. J Cell Biochem 94: 153-167
4. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430
5. Ashkenazi A (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19: 325-331
6. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305-1308
7. Ashkenazi A, Holland P, Eckhardt SG (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630
8. Barnhart BC, Alappat EC, Peter ME (2003) The CD95 type I/type II model. Semin Immunol 15: 185-193
9. Beckmann AM, Wilce PA (1997) Egr transcription factors in the nervous system. Neurochem Int 31: 477-510; discussion 517-526
10. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK (2005) Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 102: 18099-18104
11. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201: 331-340
12. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, de Vries EG (2006) The clinical trail of TRAIL. Eur J Cancer 42: 2233-2240
13. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ (1998) Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2468
14. Eskes R, Desagher S, Antonsson B, Martinou JC (2000) Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935
15. Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475
16. Fulda S, Meyer E, Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294
17. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280: 14507-14513
18. Green DR (2000) Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4
19. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305: 626-629
20. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, Schutz G, Greiner EF, Kemp CJ, Walczak H (2008) TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118: 100-110
21. Hong Y, Ho KS, Eu KW, Cheah PY (2007) A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Clin Cancer Res 13: 1107-1114
22. Huang RP, Fan Y, deBelle I, Ni Z, Matheny W, Adamson ED (1998a) Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation. Cell Death Differ 5: 96-106
23. Huang RP, Fan Y, Peng A, Zeng ZL, Reed JC, Adamson ED, Boynton AL (1998b) Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2. Int J Cancer 77: 880-886
24. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960
25. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280: 2205-2212
26. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620
27. Kobayashi D, Yamada M, Kamagata C, Kaneko R, Tsuji N, Nakamura M, Yagihashi A, Watanabe N (2002) Overexpression of early growth response-1 as a metastasis-regulatory factor in gastric cancer. Anticancer Res 22: 3963-3970
28. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM (2002) Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 277: 575-585
29. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, Johnston PG (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25: 838-848
30. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12: 773-782
31. Mahalingam D, Szegezdi E, Keane M, Jong SD, Samali A (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35(3): 280-288
32. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26: 7046-7055
33. Nakajima A, Kojima Y, Nakayama M, Yagita H, Okumura K, Nakano H (2008) Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells. Oncogene 27: 76-84
34. Papenfuss K, Cordier SM, Walczak H (2008) Death receptors as targets for anti-cancer therapy. J Cell Mol Med 12: 2566-2585
35. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS, Sistonen L, Eriksson JE (2005) Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 280: 27345-27355
36. Riggs PK, Rho O, DiGiovanni J (2000) Alteration of Egr-1 mRNA during multistage carcinogenesis in mouse skin. Mol Carcinog 27: 247-251
37. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274: 22532-22538
38. Schug J (2008) Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics Chapter 2, Unit 2.6
39. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, Robinson H, Salvesen GS, Schwarzenbacher R, Riedl SJ (2009) The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 457: 1019-1022
40. Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, Mohiuddin M, Rangnekar VM, Ahmed MM (2007) Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res 67: 11811-11820
41. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609
42. Swirnoff A, Milbrandt J (1995) DNA-binding specificity of NGFI-A and related zinc finger transcription factors. Mol Cell Biol 15: 2275-2287
43. Szegezdi E, Herbert KR, Kavanagh ET, Samali A, Gorman AM (2008) Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion via regulation of Bim. J Cell Mol Med 12: 2482-2496
44. Thiel G, Cibelli G (2002) Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287-292
45. Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, Russell DW (1996) Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol 155: 975-981
46. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 103: 8634-8639
47. van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S (2003) Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89: 363-373
48. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I (2001) The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3: 1124-1128
49. Wagner M, Schmelz K, Dorken B, Tamm I (2008) Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer 122: 1278-1287
50. Zagurovskaya M, Shareef MM, Das A, Reeves A, Gupta S, Sudol M, Bedford MT, Prichard J, Mohiuddin M, Ahmed MM (2009) EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 28: 1121-1131
51. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF (2004) Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64: 7086-7091